[Management of levodopa-induced dyskinesia].
Identifieur interne : 001113 ( PubMed/Curation ); précédent : 001112; suivant : 001114[Management of levodopa-induced dyskinesia].
Auteurs : O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L MontastrucSource :
- Revue neurologique [ 0035-3787 ] ; 2002.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Algorithms, Humans.
Abstract
There are three main therapeutic strategies to manage levodopa-induced dyskinesias in parkinsonian patients: (1) prevent the occurrence of the priming phenomenon which generates the abnormal movements, (2) avoid the expression of dyskinesias in already primed brain with antidyskinetic symptomatic interventions and (3) reverse, once primed, the changes that occurred in the basal ganglia to induce dyskinesias. To prevent, at least partly, priming for dyskinesias is attempted by the early use of dopamine D2 agonists, which delays the need for levodopa. To avoid the expression of dyskinesias in already primed patients, amantadine is presently the most efficacious symptomatic medication, while functional stereotactic surgery is required in the most severe cases. There are several ways to try to reverse, at least partly, dyskinesia priming. The strategy is to reduce as much as possible (ideally completely) the daily dose of levodopa, by the mean of adjunct interventions like high doses of oral agonists, or more efficiently, with apormorphine subcutaneous infusion or subthalamic deep brain stimulation.
PubMed: 12690671
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001154
Links to Exploration step
pubmed:12690671Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Management of levodopa-induced dyskinesia].</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Pharmacologie, Faculté de Médecine, Centre d'Investigations Cliniques, INSERM U455, 37, Allées Jules-Guesde, 31073 Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie, Faculté de Médecine, Centre d'Investigations Cliniques, INSERM U455, 37, Allées Jules-Guesde, 31073 Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ferreira, J J" sort="Ferreira, J J" uniqKey="Ferreira J" first="J J" last="Ferreira">J J Ferreira</name>
</author>
<author><name sortKey="Payoux, P" sort="Payoux, P" uniqKey="Payoux P" first="P" last="Payoux">P. Payoux</name>
</author>
<author><name sortKey="Brefel Courbon, Ch" sort="Brefel Courbon, Ch" uniqKey="Brefel Courbon C" first="Ch" last="Brefel-Courbon">Ch Brefel-Courbon</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12690671</idno>
<idno type="pmid">12690671</idno>
<idno type="wicri:Area/PubMed/Corpus">001154</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001154</idno>
<idno type="wicri:Area/PubMed/Curation">001113</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001113</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Management of levodopa-induced dyskinesia].</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name>
<affiliation wicri:level="1"><nlm:affiliation>Service de Pharmacologie, Faculté de Médecine, Centre d'Investigations Cliniques, INSERM U455, 37, Allées Jules-Guesde, 31073 Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service de Pharmacologie, Faculté de Médecine, Centre d'Investigations Cliniques, INSERM U455, 37, Allées Jules-Guesde, 31073 Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ferreira, J J" sort="Ferreira, J J" uniqKey="Ferreira J" first="J J" last="Ferreira">J J Ferreira</name>
</author>
<author><name sortKey="Payoux, P" sort="Payoux, P" uniqKey="Payoux P" first="P" last="Payoux">P. Payoux</name>
</author>
<author><name sortKey="Brefel Courbon, Ch" sort="Brefel Courbon, Ch" uniqKey="Brefel Courbon C" first="Ch" last="Brefel-Courbon">Ch Brefel-Courbon</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Algorithms</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Parkinson Disease (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Algorithms</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There are three main therapeutic strategies to manage levodopa-induced dyskinesias in parkinsonian patients: (1) prevent the occurrence of the priming phenomenon which generates the abnormal movements, (2) avoid the expression of dyskinesias in already primed brain with antidyskinetic symptomatic interventions and (3) reverse, once primed, the changes that occurred in the basal ganglia to induce dyskinesias. To prevent, at least partly, priming for dyskinesias is attempted by the early use of dopamine D2 agonists, which delays the need for levodopa. To avoid the expression of dyskinesias in already primed patients, amantadine is presently the most efficacious symptomatic medication, while functional stereotactic surgery is required in the most severe cases. There are several ways to try to reverse, at least partly, dyskinesia priming. The strategy is to reduce as much as possible (ideally completely) the daily dose of levodopa, by the mean of adjunct interventions like high doses of oral agonists, or more efficiently, with apormorphine subcutaneous infusion or subthalamic deep brain stimulation.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12690671</PMID>
<DateCreated><Year>2003</Year>
<Month>04</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Print"><Volume>158 Spec no 1</Volume>
<PubDate><Year>2002</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Management of levodopa-induced dyskinesia].</ArticleTitle>
<Pagination><MedlinePgn>S117-24</MedlinePgn>
</Pagination>
<Abstract><AbstractText>There are three main therapeutic strategies to manage levodopa-induced dyskinesias in parkinsonian patients: (1) prevent the occurrence of the priming phenomenon which generates the abnormal movements, (2) avoid the expression of dyskinesias in already primed brain with antidyskinetic symptomatic interventions and (3) reverse, once primed, the changes that occurred in the basal ganglia to induce dyskinesias. To prevent, at least partly, priming for dyskinesias is attempted by the early use of dopamine D2 agonists, which delays the need for levodopa. To avoid the expression of dyskinesias in already primed patients, amantadine is presently the most efficacious symptomatic medication, while functional stereotactic surgery is required in the most severe cases. There are several ways to try to reverse, at least partly, dyskinesia priming. The strategy is to reduce as much as possible (ideally completely) the daily dose of levodopa, by the mean of adjunct interventions like high doses of oral agonists, or more efficiently, with apormorphine subcutaneous infusion or subthalamic deep brain stimulation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Service de Pharmacologie, Faculté de Médecine, Centre d'Investigations Cliniques, INSERM U455, 37, Allées Jules-Guesde, 31073 Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ferreira</LastName>
<ForeName>J J</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Payoux</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brefel-Courbon</LastName>
<ForeName>Ch</ForeName>
<Initials>Ch</Initials>
</Author>
<Author ValidYN="Y"><LastName>Montastruc</LastName>
<ForeName>J L</ForeName>
<Initials>JL</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Prise en charge des dyskinésies par la lévodopa.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>73</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2003</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12690671</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001113 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001113 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:12690671 |texte= [Management of levodopa-induced dyskinesia]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:12690671" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |